Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives $17.25 Consensus Target Price from Brokerages

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $17.25.

AUPH has been the topic of several research reports. Bloom Burton downgraded shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reissued a “sector perform” rating and set a $15.00 price target (up from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the company from $10.00 to $21.00 in a research report on Friday, November 7th. Finally, Leerink Partners downgraded Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their target price for the company from $15.00 to $16.00 in a report on Wednesday, December 3rd.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $15.89 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.17 and a current ratio of 5.76. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 28.38 and a beta of 1.42. The business has a 50-day simple moving average of $14.95 and a two-hundred day simple moving average of $12.14. Aurinia Pharmaceuticals has a fifty-two week low of $6.55 and a fifty-two week high of $16.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.07. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. The firm had revenue of $73.47 million during the quarter, compared to analyst estimates of $67.70 million. On average, analysts expect that Aurinia Pharmaceuticals will post 0.11 earnings per share for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. MAI Capital Management bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $39,000. Northwestern Mutual Wealth Management Co. purchased a new position in Aurinia Pharmaceuticals during the third quarter valued at $48,000. State of Alaska Department of Revenue purchased a new position in Aurinia Pharmaceuticals during the third quarter valued at $91,000. Vanguard Personalized Indexing Management LLC bought a new position in Aurinia Pharmaceuticals in the 2nd quarter worth $92,000. Finally, Teza Capital Management LLC bought a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $96,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.